Navigation Links
OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
Date:10/13/2010

NEW YORK, Oct. 13 /PRNewswire/ -- OLIGOMERIX, Inc. announced today that Vic Micati, a Director since 2007, has been appointed Chairman of Oligomerix and that Jack Pasini has been appointed to the Company's Board of Directors and as Chief Commercial Officer.  

Having worked at Pfizer Inc. (PFE) for nearly 40 years, Mr. Micati was a member of Pfizer's Corporate Management Committee responsible for all aspects of global operations. He also served as Executive Vice President of the Pharmaceutical Group and Vice President of Pfizer Inc. He was appointed to the International Board of Directors in 1984 and became President of Pfizer's European operations in 1990.

Since 1999, Mr. Micati has worked as a consultant in the pharmaceutical industry and served on the board of several companies including Ilex Oncology (ILXO), subsequently acquired by Genzyme Corporation (GENZ), ENZON Pharmaceuticals Inc. (ENZN) and was member of the Advisory Board of Almirall, a Spanish pharmaceutical company.

Mr. Pasini is also a seasoned executive, having gained broad global commercial leadership experience during a 30-year career with Pfizer. Formerly, Mr. Pasini was Vice President, Worldwide Marketing responsible for Pfizer's Anti-Infective and Allergy/Respiratory Therapeutic Groups.  He also served as Vice President of Product Development, Regional President of the Africa, Middle East Region, and Vice President of Business Intelligence & Planning.  Mr. Pasini served on the board of the American Lung Association of the City of New York for five years.  Since his retirement in 2007, Mr. Pasini has worked as a consultant in the pharmaceutical industry.

"We are very pleased that Vic has agreed to take on the role of Chairman of Oligomerix and that Jack has agreed to join the Oligomerix Board and serve as Chief Commercial Officer.  We anticipate that Jack will play a key role in developing important partnerships within the industry to facilitate our transition into a full-scale biotechnology company," said James Moe, President & CEO.

ABOUT OLIGOMERIX

OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located within the Audubon Biomedical Science and Technology Park of Columbia University. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.  For more information visit www.oligomerix.com.Media Contact:Tiberend Strategic Advisors, Inc.212-827-0020Farrell Denbyfdenby@tiberendstrategicadvisors.com
'/>"/>

SOURCE OLIGOMERIX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
2. Boston Scientific Announces Global Launch of Journey™ Guidewire
3. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
4. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
5. Prime Therapeutics Announces URAC Accreditation
6. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
7. Cellectis bioresearch Announces Establishment of Subsidiary in the US
8. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
9. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
10. Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
11. Express Scripts Announces Third Quarter 2010 Earnings and 2011 Earnings Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... Australia Ophthalmic Lasers Market Outlook to 2022 ... Market Outlook to 2022", provides key market data on ... in millions of US dollars, volume (in units) and ... Femtosecond Lasers and YAG Lasers. The report also ... of these market segements, and global corporate-level profiles of ...
(Date:12/8/2016)... Global Interventional Radiology Market: Scope and ... radiology market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc ... Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: ... , Results of the comparative usability study demonstrate that a dictation-based method (“NLP ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... With the ... created the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about ... Dentistry, the dental implant and prosthetic market in the U.S. is projected to reach ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
Breaking Medicine News(10 mins):